Highly purified EPA for treatment of schizophrenia and related disorders
AssigneeLaxdale Limited
InventorsMalcolm Peet, Krishna S Vaddadi
Life of this patent
Estimating the term…
Abstract
A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
Claims21
A method of treating schizophrenia, a schizoaffective disorder, or a schizotypal disorder in a subject comprising administering to the subject a pharmaceutical preparation comprising EPA in an appropriately assimilable form, wherein of all the fatty acids present in the preparation at least 90% is in the form of EPA, and wherein less than 5% is in the form of docosahexaenoic acid (DHA), in conjunction with a drug which acts primarily on neurotransmitter metabolism or receptors.
A method of treating schizophrenia, a schizoaffective disorder, or a schizotypal disorder in a subject comprising administering to the subject a pharmaceutical preparation comprising EPA in an appropriately assimilable form, wherein of all the fatty acids present in the preparation at least 90% is in the form of EPA, and wherein less than 5% is in the form of docosahexaenoic acid (DHA).
Dependencies are inferred from the claim text.